Antiviral composition for use in prophylactic or post-exposure treatment of infectious or respiratory diseases and use thereof
Patent Information
- Application Number
- HK42026126151
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-01-07
- Filing Date
- 2026-07-15
- Publication Date
- 2026-09-11
Smart Images

Figure 00000028_0000 
Figure 00000029_0000 
Figure 00000030_0000
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202511352966.6 (22) Application Date 2021.03.22 (30) Priority Data 62 / 993,060 2020.03.22 US 63 / 017,297 2020.04.29 US 63 / 134,645 2021.01.07 US (62) Divisional Application Data 202180023098.0 2021.03.22 (71) Applicant Yingbo Biotechnology Co., Ltd. Address Taipei City, Taiwan, China (72) Inventors Dai Tianci, Zeng Yunlong, Zheng Tingyu, Shi Xuefang, Chen Heru, Hong Jilong, Fang Yuancheng (74) Patent Agency Yongxin Patent & Trademark Agency Co., Ltd. 72002 Patent Attorney Guo Xiaodong (51) Int.Cl. A61K 31 / 706 (2006.01) A61K 9 / 16 (2006.01) A61K 9 / 72 (2006.01) A61P 31 / 16 (2006.01) A61P 31 / 14 (2006.01) A61P 11 / 00 (2006.01) A61P 9 / 00 (2006.01) A61P 1 / 16 (2006.01) (54) Title of Invention: Antiviral Composition for Prevention or Post-Exposure Treatment of Infections or Respiratory Diseases and Its Use Therein (57) Abstract: This application relates to an antiviral composition for prevention or treatment of pathogenic infections and its use therein. The liposomal antiviral agent of the composition comprises liposomes and an antiviral agent embedded in the liposomes. The antiviral agent is stably encapsulated in liposomes, and it has been demonstrated that the resulting liposomal antiviral agent can be stably aerosolized or nebulized for administration via inhalation to treat individuals in need while reducing side effects. Claims 4 pages, Description 23 pages, Drawings 4 pages. CN 121401286 A 2026.01.27 CN 1 21 40 12 86 A 1. An antiviral composition for inhalation administration comprising a liposomal antiviral agent, wherein the liposomal antiviral agent comprises: liposomes, the liposomes comprising at least one lipid, a trapping agent, and an antiviral agent; wherein the antiviral agent is encapsulated in the liposomes by the trapping agent, wherein the trapping agent is composed of an ammonium compound and an anion-counterion, wherein the molar ratio of the antiviral agent to the lipid is from 0.01 mol / mol to 2.0 mol / mol, and wherein the antiviral agent is a nucleoside compound of structural formula (I): (I).Each R1, R2, R3, R4, or R5 is independently hydrogen, ORa, N(Ra)2, N3, CN, NO2, S(O)nRa, halogen, or methyl, where n is 0, 1, or 2; R6 is CN or hydrogen; each Ra is independently H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, aryl(C1-C8)alkyl, (C4-C8)carbocycloalkyl, -C(=O)R11, -C(=O)OR11, -C(=O)NR11R12, -C(=O)SR11, -S(O)R11, -S(O)2R11, -S(O)(OR11), -S(O)2(OR11), or -SO2NR11R12; and R7 is hydrogen; each X1 or X2 is independently C-R10 or N; R8 can be a halogen, NR11R12, N(R11)(OR11), NR11NR11R12, N3, NO, NO2, CHO, CN, —CH(=NR11), —CH=NHNR11, —CH=N(OR11), —CH(OR11)2, —C(=O)NR11R12, —C(=S)NR11R12, —C(=O)OR11, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, aryl(C1-C8)alkyl, (C4-C8)carbocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —C(=O)(C1-C8)alkyl, —S(O)n(C1-C8)alkyl, aryl(C1-C8)alkyl, OR11 or SR11. Each aryl or heteroaryl group is independently and optionally substituted by one or more Z groups; each R9 or R10 is independently hydrogen, halogen, R11, OR11, SR11, NR11R12, N(R11)(OR11), NR11NR11R12, N3, NO, NO2, CHO, CN, —CH(=NR11), —CH=NHNR11, —CH=N(OR11), —CH(OR11)2, —C(=O)NR11R12, —C(=S)NR11R12, —C(=O)OR11; Each R11 or R12 is independently hydrogen, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)ynyl, (C4-C8)carbocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=O)(C1-C8)alkyl, -S(O)n(C1-C8)alkyl, or aryl(C1-C8)alkyl, wherein each aryl or heteroaryl is independently optionally substituted by one or more Z groups; or R11 or R12 together with the nitrogen to which both are attached forms a 3- to 7-membered heterocycle.Any carbon atom in the heterocycle may optionally be replaced by —O—, —S— or —NRa—; each Z group is independently a halogen, —O—, =O, —ORb, —SRb, —S—, —NRb2, —N+Rb3, =NRb, —CN, —OCN, —N=C=O, —NCS, —NO, —NO2, =N2, —N3, —NHC(=O)Rb, —OC(=O)Rb, —NHC(=O)NRb2, —S(=O)2—, —S(=O)2OH, —S(=O)2Rb, —OS(=O)2ORb, —S(=O)2OH, —S(=O)Rb, —OP(=O) (ORb)2, —P(=O)(ORb)2, —P(=O)(O-)2, —P(O)(ORb)(O-), —C(=O)Rb, —C(=O)X, —C(S)Rb, —C(O)ORb, —C(O)O-, —C(S)ORb, —C(O)SRb, —C(S)SRb, —C(O)NRb2, —C(S)NRb2, —C(=NRb)NRb2, wherein each Rb is independently hydrogen, alkyl, aryl, aralkyl or heterocyclic, wherein one or more non-terminal carbon atoms in each of the (C1-C8) alkyl groups are optionally replaced by —O—, —S— or —NRa—. 2. The antiviral composition of claim 1, wherein the antiviral agent is selected from: [list of ingredients - likely a specific ingredient or a specific ingredient], ... 6. The antiviral composition of claim 1, wherein the average particle size of the liposome-based antiviral agent ranges from 50 nm to 1000 nm. 7. The antiviral composition of claim 1.The anions and counterions are selected from: sucrose octasulfate, dextran sulfate, sulfate, citrate, gluconic acid, sulfonate, phosphate, pyrophosphate, tartrate, succinate, maleic acid, borate, carboxylate, bicarbonate, glucuronide, chloride, hydroxide, nitrate, cyanate, bromide, and combinations thereof. 8. The antiviral composition of claim 3, wherein the liposomes further comprise polyethylene glycol (PEG) modified lipids, the amount of which, based on total lipids, is from 0.0001 mol% to 10 mol%. 9. The antiviral composition of claim 8, wherein the PEG-modified lipids have a polyethylene glycol portion with an average molecular weight ranging from about 1,000 g / mol to about 5,000 g / mol. 10. The antiviral pharmaceutical composition of claim 8, wherein the polyethylene glycol-modified lipid is 1,2-distearate-sn-glycerol-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)] (DSPE-PEG). 11. The antiviral pharmaceutical composition of claim 10, wherein the amount of DSPE-PEG is from about 0.001 mol% to about 5 mol% based on total phospholipids and sterols. 12. The antiviral composition of claim 1, further comprising an antibiotic. 13. The antiviral composition of claim 12, wherein the antibiotic is selected from azithromycin and azithromycin. 14. The antiviral composition of claim 1, wherein the concentration of the lipid is from 1 mM to 100 mM. 15. The antiviral composition of claim 1, further comprising a free antiviral agent. 16. The antiviral composition of claim 1, wherein the molar ratio of the antiviral agent to the lipid is from 0.05 mol / mol to 2.0 mol / mol. Claims 3 / 4, page 4, CN 121401286 A 17. The antiviral composition of claim 1, wherein the amount of said antiviral agent is from about 0.1 mg / mL to about 80 mg / mL. 18. The antiviral composition of claim 1, wherein said antiviral composition is a nebulized spray. 19. An aerosolized particulate composition comprising the antiviral composition of any one of claims 1 to 18, said aerosolized particulate composition being for administration via inhalation to prevent or treat infectious or respiratory diseases. 20. The aerosolized particulate composition of claim 19.The median aerodynamic diameter of the plurality of particles is about 0.5 µm to about 5 µm. 21. Use of the antiviral composition of any one of claims 1 to 18 in the preparation of a medicament for treating or preventing infectious or respiratory diseases. 22. The use of claim 21, wherein the respiratory disease is selected from: acute respiratory infection including severe pneumonia (SARI), acute respiratory distress syndrome (ARDS), sepsis, and septic shock. 23. The use of claim 21, wherein the infectious disease is caused by influenza virus, retrovirus, coronavirus, or SARS-CoV-2. 24. Use of the antiviral composition of any one of claims 1 to 18 in the preparation of a medicament for reducing complications associated with the treatment of respiratory or infectious diseases in human individuals. 25. The use of claim 24, wherein the complications include cardiotoxicity or hepatotoxicity. 26. The use of claim 24, wherein the complications include prolongation of the corrected QT interval (QTc). Claims 4 / 4 Page 5 CN 121401286 A Antiviral Composition for Prevention or Post-Exposure Treatment of Infections or Respiratory Diseases and Its Use Thereof
[0001] This application is a divisional application of Chinese Patent Application No. 202180023098.0, filed on March 22, 2021, entitled "Antiviral Composition for Prevention or Post-Exposure Treatment of Infections or Respiratory Diseases". Technical Field
[0002] The present invention relates to a drug delivery system for delivering antiviral agents. The present invention relates to a method for preparing the drug delivery system. The present invention also relates to a sustained-release drug composition suitable for pulmonary delivery systems, which has reduced systemic side effects. The present invention also relates to the use of the drug composition. Background Art
[0003] Infectious diseases can be transmitted through various routes such as contact, droplets and bloodborne infections. Systemic administration can reduce the bioavailability of drugs in the affected body environment. The penetration of drug delivery systems into target cells of target tissues is a key obstacle to the effective treatment of infectious diseases, such as pulmonary infections treated by inhalation. Although the drug remains within the liposome before attaching to the target epithelial cells, it can be converted from one liposomal drug to another depending on the diffusion rate of the free and uncharged drug across the liposome membrane. This largely depends on the physicochemical properties of the lipid barrier present in the microenvironment outside the liposome, and the water environment within the liposome.
[0004] Respiratory diseases caused by infection or other unknown reasons are extremely serious and debilitating lung diseases.It can cause early death, especially in diseases characterized by efficient viral replication and cell damage caused by virus-induced cell lysis or immunopathology. Infected cell lines and post-mortem lung tissue have shown cytopathic effects due to apoptosis, necrosis, or occasionally syncytial formation.
[0005] As described in U.S. Patent Publication No. US20110104259A1, liposomes have been used as drug carriers to mask the unpleasant taste of drugs used for the treatment of asthma via inhalation. Liposome encapsulation of drugs can alter the pharmacokinetic characteristics of drugs, provide slow drug release in a local body environment, enable the administration of optimal dosage with less drug administration frequency, and / or reduce side effects and toxicity. However, it is unclear whether quinine compounds or other antiviral agents delivered via liposomes by inhalation can effectively perform their desired functions, such as deposition on target cell lines expressing suitable receptors as target sites, while simultaneously serving as intracellular target sites for viral entry and performing the desired pharmacokinetic properties in vivo.
[0006] It remains unclear whether liposome technology, using reformulated antiviral agents, can produce inhaled liposomal formulations for prophylactic use to prevent severe acute respiratory syndrome (ARDS) or for therapeutic use to treat respiratory or infectious diseases with reduced side effects. Currently, there are no viable inhaled liposomal drug formulations for chemopreventive use to prevent or treat mild cases, acute respiratory distress syndrome (ARDS), acute lung injury (ALI), or severe acute respiratory syndrome (SARS) caused by viral infections such as coronaviruses, COVID-19 (also known as SARS-CoV2).
[0007] There remains a need for an inhalable formulation with predetermined encapsulation efficiency that balances the frequency and / or dosage of antiviral agents (such as quinine and nucleoside compounds) with the prophylactic or therapeutic window required for lung delivery. In addition, formulations suitable for respiratory diseases should have the following characteristics: they are inhalable, exhibit sufficient encapsulation efficiency after nebulization (see page 1 / 23 of the instruction manual, 6 CN 121401286 A), have improved stability or appropriate resistance to damage caused by local pulmonary surfactants, and further have the desired dose strength to ensure the potential to achieve the desired efficacy in the pulmonary environment. The present invention addresses this and other needs. Summary of the Invention
[0008] The present invention provides a liposomal pharmaceutical formulation for treating respiratory or infectious diseases, particularly by inhalation, comprising at least one lipid (optionally phospholipids and sterols, and / or phospholipids modified with polyethylene glycol (PEG), and an antiviral agent encapsulated in the aqueous interior of the liposome.
[0009] In order to improve existing treatment modalities for respiratory or infectious diseases,Taking advantage of the benefits of slow, sustained drug release, we have developed an antiviral composition comprising a liposomal antiviral agent and a predetermined amount of free antiviral agent in an aqueous suspension, which can be aerosolized and inhaled for the prevention or enhanced treatment of respiratory diseases. There is a particular need for an inhalable formulation for the prevention or treatment of SARS.
[0010] This disclosure provides an antiviral composition for the prevention or treatment of respiratory or infectious diseases, particularly for SARS, which has the following advantages: 1) longer therapeutic effect compared to inhaled free drug components; 2) direct delivery of the drug to the disease site or site of viral infection; 3) faster onset of action; 4) reduced adverse drug reactions and systemic effects; 5) bypassing first-pass metabolism observed in oral administration, thereby improving the bioavailability of the drug component (and potentially reducing hepatotoxicity, ocular symptoms of retinopathy, gastrointestinal (GI) effects, including nausea, vomiting, diarrhea, abdominal discomfort, and hepatotoxicity); 6) increased residence time of the drug component in target tissues through sustained release from liposomal drugs; 7) reduced frequency of drug administration; 8) non-invasive inhalation delivery; and / or 9) improved patient outcomes and compliance.
[0011] In a particular embodiment, the antiviral agent according to the present disclosure is encapsulated in liposomes in a predetermined amount to form an antiviral agent composition according to the present disclosure, thereby achieving a composition having preferred release characteristics and reduced toxicity (particularly cardiotoxicity).
[0012] An antiviral agent composition for the prevention or treatment of respiratory or infectious diseases is provided, which is inhalable and comprises a liposomal antiviral agent, wherein the liposomal antiviral agent comprises: a liposome containing at least one lipid, and an antiviral agent encapsulated in the liposome.
[0013] In some embodiments, the liposome comprises a lipid bilayer consisting of one or more phospholipids and sterols, wherein the sterol is cholesterol, and the molar ratio of the one or more phospholipids to the sterols is 1:1 to 2:1, with a selectivity of 3:2.
[0014] In some embodiments, the one or more phospholipids include phosphocholine (PC), which may include, but is not limited to, hydrogenated soybean phosphatidylcholine (HSPC), 1,2-distearoyl-sn-glycero-3-phosphocholine,DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), or mixtures thereof. In other embodiments, the one or more phospholipids comprise DSPC and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) in a molar ratio of 1:1 or 3:2.
[0015] In some embodiments, the liposome-based antiviral agent comprises a 4-aminoquinoline compound.
[0016] In some embodiments, the 4-aminoquinoline compound is selected from the group consisting of chloroquine, hydroxychloroquine, and amodiaquine.
[0017] In some embodiments, the antiviral agent is a nucleoside compound as shown in structural formula I: (I), each R1, R2, R3, R4 or R5 is independently hydrogen, ORa, N(Ra)2, N3, CN, NO2, S(O)nRa, halogen or methyl, wherein n is 0, 1 or 2; R6 is CN or hydrogen; each Ra is independently hydrogen, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, aryl(C1-C8)alkyl, (C4-C8)carbocycloalkyl, -C(=O)R11, -C(=O)OR11, -C(=O)NR11R12, -C(=O)SR11, -S(O)R11, -S(O)2R11, -S(O)(OR11), -S(O)2(OR11), or -SO2NR 11R12; and R7 is hydrogen; each X1 or X2 is independently C-R10 or N; R8 is halogen, NR11R12, N(R11)(OR11), NR11NR11R12, N3, NO, NO2, CHO, CN, —CH(=NR11), —CH=NHNR11, —CH=N(OR11), —CH(OR11)2, —C(=O)NR11R12, —C(=S)NR11R12, —C(=O)OR11, (C1- (C8)alkyl, (C2-C8)alkenyl, (C2-C8)ynyl, aryl(C1-C8)alkyl, (C4-C8)carbocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=O)(C1-C8)alkyl, -S(O)n(C1-C8)alkyl, aryl(C1-C8)alkyl, OR11 or SR11,Each aryl or heteroaryl group is independently and optionally substituted by one or more Z groups; each R9 or R10 is independently hydrogen, halogen, R11, OR11, SR11, NR11R12, N(R11)(OR11), NR11NR11R12, N3, NO, NO2, CHO, CN, —CH(=NR11), —CH=NHNR11, —CH=N(OR11), —CH(OR11)2, —C(=O)NR11R12, —C(=S)NR11R12, —C(=O)OR11; Each R11 or R12 is independently hydrogen, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)ynyl, (C4-C8)carbocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=O)(C1-C8)alkyl, -S(O)n(C1-C8)alkyl, or aryl(C1-C8)alkyl, wherein each aryl or heteroaryl is independently optionally substituted by one or more Z groups; or R11 or R12 together with the nitrogen attached to both of them forms a 3- to 7-membered heterocycle, wherein any carbon atom in the heterocycle may optionally be substituted by -O-, -S-, or -NRa-; each Z group is independently halogen, -O-, =O, -ORb, -SRb, -S-, -NRb2, -N+Rb3, =NRb, - CN, —OCN, —SCN, —N=C=O, —NCS, —NO, —NO2, =N2, —N3, —NHC(=O)Rb, —OC(=O)Rb, —NHC(= O)NRb2, —S(=O)2—, —S(=O)2OH, —S(=O)2R b, —OS(=O)2OR b, —S(=O)2OH, —S(=O)Rb, —OP(= O)(ORb)2, —P(=O)(ORb)2, —P(=O)(O‑)2, —P(O)(ORb)(O‑), —C(=O)Rb, —C(=O)X, —C(S) Rb, -C(O)ORb, -C(O)O-, -C(S)ORb, -C(O)SRb, -C(S)SRb, -C(O)NRb2, -C(S)NRb2, -C(=NRb)NRb2, wherein each Rb is independently hydrogen, alkyl, aryl, aralkyl, or heterocyclic; wherein one or more non-terminal carbon atoms in each of the (C1-C8) alkyl groups are optionally replaced by -O-, -S-, or -NRa-.
[0018] In some embodiments,The antiviral composition according to the invention further comprises an antibiotic, a supplement, an antiretroviral drug, or a combination thereof. Examples of antibiotics include penicillins (ampicillin + sulbactam, piperacillin + tazobactam), macrolides, cephalosporins, aminoglycosides, and glycopeptides. In some embodiments, the antibiotic is selected from curlimycin and azithromycin.
[0019] On the other hand, the present invention also provides an antiviral agent composition for the prevention or treatment of respiratory or infectious diseases, or an aerosolized particulate composition comprising said antiviral agent composition, having a drug-to-lipid ratio of at least 0.01 mol / mol, and optionally between 0.01 mol / mol and 2.0 mol / mol, between 0.05 mol / mol and 2.0 mol / mol, between 0.05 mol / mol and 1.5 mol / mol, between 0.05 mol / mol and 1.0 mol / mol, between 0.05 mol / mol and 0.5 mol / mol, between 0.05 mol / mol and 0.3 mol / mol, between 0.05 mol / mol and 0.2 mol / mol, between 0.05 mol / mol and 0.15 mol / mol, between 0.01 mol / mol and 1 mol / mol, between 0.05 mol / mol and 0.05 mol / mol. The concentration ranges from 0.1 mol / mol to 0.07 mol / mol to 0.09 mol / mol, or about 0.085 mol / mol. The concentration of the antiviral agent ranges from 0.1 mg / mL to 10 mg / mL.
[0020] On the other hand, this disclosure also provides an aerosolized particulate composition according to the invention for the prevention or treatment of respiratory diseases, comprising a liposomal quinine compound and having a drug-to-lipid ratio of at least 0.01 mol / mol, optionally at least 0.05 mol / mol.Optionally, the concentration is between 0.01 mol / mol and 2.0 mol / mol, between 0.05 mol / mol and 2.0 mol / mol, between 0.05 mol / mol and 1.5 mol / mol, between 0.05 mol / mol and 1.0 mol / mol, between 0.05 mol / mol and 0.5 mol / mol, between 0.05 mol / mol and 0.3 mol / mol, between 0.05 mol / mol and 0.2 mol / mol, between 0.05 mol / mol and 0.15 mol / mol, optionally 0.5 mol / mol, and the concentration of the quinine compound is between 1 mg / mL and 10 mg / mL based on the composition.
[0021] On the other hand, this disclosure also provides an aerosolized particulate composition according to the invention for the prevention or treatment of respiratory diseases, comprising a liposome-like nucleoside compound and having a drug-to-lipid ratio of at least 0.01 mol / mol, optionally at least 0.05 mol / mol, optionally between 0.01 mol / mol and 1.0 mol / mol, between 0.03 mol / mol and 0.5 mol / mol, between 0.03 mol / mol and 0.15 mol / mol, between 0.03 mol / mol and 0.1 mol / mol, optionally about 0.05 mol / mol, between 0.05 mol / mol and 0.5 mol / mol, between 0.05 mol / mol and 0.15 mol / mol, between 0.05 mol / mol and 0.1 mol / mol, between 0.07 mol / mol and 0.1 mol / mol. The concentration of the nucleoside compound is between 0.1 mg / mL and 5 mg / mL based on the composition, optionally between 0.085 mol / mol.
[0022] On the other hand, the present invention also provides an aerosol spray comprising an antiviral composition for use according to the present invention.
[0023] On the other hand, the present invention also provides an aerosolized particulate composition for the prevention or treatment of respiratory diseases or infectious diseases according to the present invention, the particulate composition comprising an antiviral agent composition and comprising a liposomal antiviral agent according to the present invention.
[0024] On the other hand, the present invention also provides a method for the prevention or treatment of respiratory diseases or infectious diseases, comprising: administering an effective amount of the antiviral agent composition according to the present invention for the prevention or treatment of respiratory diseases to an individual in need of such treatment.
[0025] On the other hand,The present invention also provides a system for administering an antiviral composition to an individual in need. This system includes an antiviral composition according to the invention, and a pulmonary delivery device. The pulmonary delivery device is capable of nebulizing the antiviral composition, and the nebulized particles comprising a plurality of liposomal antiviral agents contain both free antiviral agents and liposomal antiviral agents, the amount of which effectively provides immediate antiviral activity, while the amount of which effectively provides sustained antiviral activity.
[0026] On the other hand, the present invention also provides a method for reducing complications associated with the treatment of respiratory or infectious diseases in human individuals having said complications, the method comprising administering an antiviral composition according to the present disclosure to an individual in need. According to the invention, the complications include, but are not limited to, cardiotoxicity or hepatotoxicity. According to the invention, the complications include, but are not limited to, correction of QT interval (QTc) prolongation.
[0027] Other objects, advantages, and novel features of the present disclosure will become more apparent when described in detail below in conjunction with the accompanying drawings.
[0028] Figure 1 is a pharmacokinetic curve of HCQ in rat lungs after administration of the composition according to the present disclosure and free HCQ.
[0029] Figure 2 is a pharmacokinetic curve of HCQ in rat blood after administration of the composition according to the present disclosure and free HCQ.
[0030] Figure 3 is a pharmacokinetic curve of HCQ in rat heart after administration of the composition according to the present disclosure and free HCQ.
[0031] Figures 4A and 4B are a series of average concentration-time curves describing the rat lungs (Figure 4A) and rat plasma (Figure 4B) after a single intravenous injection of GS-441524 (GS-441524 solution-IV) prepared by SBECD, or after intratracheal administration of liposome-formed GS-441524 (also known as ISPM21) (ISPM21-IT); LLOQ: lower limit of quantitation. Detailed Description
[0032] Definitions Unless otherwise stated, the following terms used as above and throughout the invention should be understood to have the following meanings.
[0033] The singular forms “a,” “an,” “the,” and “this” as used herein include plural referents unless the context clearly indicates otherwise.
[0034] All numbers herein are to be understood to be modified by “about,” and when referring to measurable values such as amount, duration, etc., it means including variables of ±10%, preferably ±5%, more preferably ±1%, and even more preferably ±0.1% of a specific value, which are applicable to describing the desired amount of the liposome-like drug.Unless otherwise stated.
[0035] The term “treating, treated, or treatment” as used herein includes preventative (e.g., prophylactic), palliative, and curative uses or results. The term “subject” includes a vertebrate suffering from a respiratory disease or other disease or suspected viral infection. Preferably, the subject is a warm-blooded animal, including mammals, preferably humans.
[0036] The term “drug” as used herein refers to an antiviral agent, such as a quinine compound or nucleoside compound according to this disclosure that relates to desired therapeutic activity. The term “drug to lipid ratio” (D / L) as used herein refers to the ratio of an antiviral agent to at least one lipid in a composition according to this disclosure. The drug content in the free or liposomal form of the liposomal pharmaceutical composition according to this disclosure is determined by, but not limited to, ultraviolet-visible (UV-Vis) absorbance or high-performance liquid chromatography (HPLC). The content or concentration of phospholipids in liposomes and liposomal drug products can be determined by, but is not limited to, the following methods: using a phosphorus assay (adapted from G. Rouser et al., Lipids 1970, 5, 494-496) or HPLC method to determine the phosphorus content of liposomes and liposomal drug product samples.
[0037] As used herein, although pharmacokinetic data have been obtained in rats, pharmacokinetic characteristics related to the inhaled compositions according to this disclosure may also be obtained in other mammals, including but not limited to cats, dogs, horses, mice, pigs, non-human primates, and humans.
[0038] Infectious diseases and respiratory diseases As used herein, infectious diseases and pathogenic infections refer to diseases caused by organisms such as viruses, parasites, and bacteria. In one aspect, infectious diseases are transmitted through fecal-oral transmission, droplet contact, sexual transmission, oral transmission, direct contact, transmission via transportation, vertical transmission, iatrogenic transmission, vector transmission, etc. On the other hand, infectious diseases may include, but are not limited to, urinary tract infections, skin infections, respiratory infections, dental infections, vaginal infections, and intraamniotic infections.
[0039] In some embodiments, the infectious diseases include, but are not limited to, acute flaccid myelitis.Anthrax, anaplasmosis, babesiosis, botulism, brucellosis, campylobacteriosis, carbapenem-resistant infection (CRE / CRPA), chancroid, chikungunya virus infection, chlamydia, ciguatella (harmful algal bloom, HABS), clostridium difficile infection, epsilon toxin, coccidioidomycosis (rib valley fever), COVID-19, Creutzfeldt-jacob disease, infectious spongiform encephalopathy (CJD), cryptosporidiosis, cyclosporidiosis, dengue fever (Dengue I, II, III, IV), diphtheria, Escherichia coli infection, Shiga toxin production. Toxin-producing (STEC), Eastern equine encephalitis (EEE), Ebola hemorrhagic fever, ehrlichiosis, encephalitis, arbovirus or parainfectious diseases, enterovirus infection, non-polio enterovirus, enterovirus infection D68 (EV-D68), giardiasis, glanders, gonococcal infection (gonorrhea), granuloma inguinale, Haemophilus influenzae disease (HIB or h-flu), Hantavirus pulmonary syndrome (HPS), hemolytic uremic syndrome (HUS), hepatitis A (Hep A), hepatitis B (Hep B), hepatitis C (Hep C), hepatitis D (Hep D), hepatitis E (Hep E), herpes, shingles, histoplasmosis Infection, human immunodeficiency virus / AIDS (HIV / AIDS), human papillomavirus (HPV), influenza, lead poisoning, Legionnaires' disease, leprosy (Hansens' disease), leptospirosis, listeriosis (Listeria,Listeria, Lyme disease, Lymphogranuloma venereum (LGV), Malaria, Measles, Glandular rhinitis, Meningitis, Viral meningitis, Meningococcal disease, Bacterial meningitis, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Multisystem inflammatory syndrome in children (MIS-C), Mumps, Norovirus, Ciguatera poisoning, Lice infestation (lice, head lice), Pelvic inflammatory disease (PID), Pertussis, Plague, Bubonic plague, Septicemic plague, Pneumonic plague, Pneumococcal disease (pneumonia), Polio, Powassan encephalitis, Psittacosis, Crabs, Public lice Infestation), impetigo (small pox, monkeypox, cowpox), Q fever, rabies, ricin poisoning, rickettsial disease (Rocky Mountain spotted fever), rubella (including congenital (German measles)), salmonellosis gastroenteritis (Salmonella), scabies infection (scabies), scombroid, septic shock (septicemia), severe acute respiratory syndrome (SARS), shigellosis gastroenteritis (Shigella), smallpox, staphylococcal infection, methicillin-resistant Staphylococcus aureus infection. (Instructions for use, page 6 / 23, 11 CN 121401286 A) (MRSA), Staphylococcal food poisoning, Enterotoxin-B poisoning (Staphylococcal food poisoning), Staphylococcal infection vancomycin intermediate (VISA), Vancomycin-resistant Staphylococcus infection (VRSA), Group A Streptococcus infection (invasive, strep-A), Group B Streptococcus infection (Strep-B), Streptococcal toxic-shock syndrome (STSS, TSS), Syphilis (primary, secondary, early latent, late latent, congenital), Tetanus infection, Tetanus (lock jaw), Trichomoniasis, Trichinosis, Tuberculosis (TB), Latent tuberculosis infection (LTBI), Tularemia (rabbit fever),tularemia), typhus (Group D), typhus, bacterial vaginosis (yeast infection), e-cigarette-associated lung injury, varicella-cholerae (cholera), vibriosis (Vibrio), viral hemorrhagic fever (Ebola virus, Lasa virus, Marburg virus), West Nile virus infection, yellow fever, Yersenia, and Zika virus infection.
[0040] According to this disclosure, respiratory diseases include, but are not limited to: acute respiratory distress syndrome (ARDS), acute lung injury (ALI), or severe acute respiratory syndrome (SARS), whose major complications include: fluid inflow into the lungs causing dyspnea or impaired breathing. Typical symptoms include fever, cough, wet cough, dry cough, dyspnea, fatigue or myalgia, chest tightness, and gradually developing shortness of breath. Complications include pulmonary hypertension, heart failure, pneumonia, or pulmonary embolism.
[0041] In some embodiments, the antiviral compositions according to this disclosure are suitable for the prevention and treatment of mild cases, and also for the treatment of acute respiratory distress syndrome (ARDS), acute lung injury (ALI), or severe acute respiratory syndrome (SARS) caused by coronaviruses or their derivatives.
[0042] Liposomes and liposomal antiviral agents As used herein, the term "liposome" or "liposomal" refers to a group of vesicles, each characterized by having an aqueous internal space that is isolated from the external medium by one or more bilayer membranes. The bilayer membranes of liposomes are typically formed of one or more lipids, i.e., amphiphilic molecules of synthetic or natural origin, which contain spatially separated hydrophobic regions and hydrophilic ends.
[0043] The aqueous internal space of liposomes is substantially free of neutral lipids, such as triglycerides, non-aqueous phases (oil phases), water-oil emulsions, second liposomes, or other mixtures containing non-aqueous phases. Non-limiting examples of liposomes include small unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs), and multilamellar vesicles (MLVs).These vesicles have average diameters ranging from 50 nm to 10,000 nm, 50 nm to 500 nm, 50 nm to 450 nm, 50 nm to 400 nm, 50 nm to 350 nm, 50 nm to 300 nm, 50 nm to 250 nm, 50 nm to 200 nm, 100 nm to 500 nm, 100 nm to 450 nm, 100 nm to 400 nm, 100 nm to 350 nm, 100 nm to 300 nm, 100 nm to 250 nm, or 100 nm to 200 nm. These average diameters are permeable to sterile filtration membranes. For example, MLVs can be formed directly from hydrated lipid membranes, spray-dried powders, or lyophilized cakes of selected lipid compositions with a trapping agent; while SUVs and LUVs can be sized from MLVs by ultrasonication, homogenization, microfluidization, or extrusion.
[0044] Generally, liposomes typically comprise a mixture of lipids containing at least one lipid selected from the group consisting of: dilipoprotein lipids, such as phospholipids, diglycerides, and dilipoglycolipids; monolipids, such as sphingomyelin and glycosphingolipids; sterols, such as cholesterol; and derivatives thereof, and combinations thereof.
[0045] Examples of phospholipids according to this disclosure include, but are not limited to: 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine). Phosphocholine (PSPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine,POPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), hydrogenated soy phosphatidylcholine (HSPC), 1,2-dimyristoyl-sn-glycero-3-phosphate-(1'-racemic-glycerol) (sodium salt) (DMPG), 1,2-dipalmitoyl-sn-glycero-3-phosphate-(1'- Racemic-glycerol (sodium salt) (1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt), DPPG); 1-palmitoyl-2-stearoyl-sn-glycerol-3-phosphate-(1'-rac-glycerol) (sodium salt), PSPG); 1,2-distearoyl-sn-glycerol-3-phosphate-(1'-rac-glycerol) (sodium salt), DSPG); 1,2-dioleoyl-sn-glycerol-3-phosphate-(1'-rac-glycerol) (sodium salt), DSPG; 1,2-dioleoyl-sn-glycerol-3-phosphate-(1'-rac-glycerol) (1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol), DOPG), 1,2-dimyristoyl-sn-glycero-3-phospho-L-serine (sodium salt), DMPS), 1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine (sodium salt),DPPS), 1,2-distearoyl-sn-glycero-3-phosphate-L-serine (sodium salt), 1,2-dioleoyl-sn-glycero-3-phosphate-L-serine (DOPS), 1,2-dimyristoyl-sn-glycero-3-phosphate (sodium salt), 1,2-dimyristoyl-sn-glycero-3-phosphate (sodium salt), 1,2-dipalmitoyl-sn-glycero-3-phosphate (sodium salt), 1 1,2-distearoyl-sn-glycero-3-phosphate (sodium salt), DSPA; 1,2-dioleoyl-sn-glycero-3-phosphate (sodium salt), DOPA; (See instruction manual, page 8 / 23, CN 121401286 A) 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE); 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE); 1 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (1'-myo-inositol) (ammonium salt)DPPI), 1,2-distearoyl-sn-glycero-3-phosphoinositol (ammonium salt), DSPI), 1,2-dioleoyl-sn-glycero-3-phospho-(1'-myo-inositol) (ammonium salt), DOPI), cardiolipin, L-α-phosphatidylcholine (EPC), and L-α-phosphatidylethanolamine (EPE).
[0046] The liposome-based antiviral agent according to this disclosure may optionally incorporate a large amount of polyethylene glycol moiety into the vesicle surface. This can be achieved by incorporating polyethylene glycol-modified phosphatidylethanolamine (PE) into the vesicle membrane to achieve a longer and more sustained drug release, which is safe, effective, and reduces the frequency of administration.
[0047] The liposome-based antiviral agent according to this disclosure may optionally bind a large amount of modified negatively charged moiety to the vesicle surface by incorporating polyethylene glycol-modified phosphatidylethanolamine (PE) or fatty acids into the vesicle membrane to prevent the aggregation or flocculation of liposomes in storage solution.
[0048] The polyethylene glycol-modified lipid comprises a polyethylene glycol moiety conjugated with the lipid. In some embodiments, the polyethylene glycol moiety has a molecular weight from about 500 to about 20,000 Daltons. In one specific embodiment, the polyethylene glycol-modified lipid is mixed with phospholipids to form liposomes having one or more bilayer membranes. In some embodiments, based on the total amount of phospholipids and sterols, the amount of polyethylene glycol-modified lipid is from 0.0001 mol% to 40 mol%, optionally from 0.001 mol% to 30 mol%, optionally from 0.01 mol% to 20 mol%, optionally from 0.001 mol% to 10 mol%, optionally from 0.001 mol% to 5 mol%, and particularly not exceeding 6 mol%, optionally not exceeding 5 mol%, not exceeding 3 mol%, or not exceeding 2 mol%. In some embodiments, the polyethylene glycol-modified lipid has a polyethylene glycol moiety.The polyethylene glycol moiety has an average molecular weight ranging from 1,000 g / mol to 5,000 g / mol. In some embodiments, the polyethylene glycol-modified lipid is phosphatidyl-ethanolamine (PEG-PE) linked to a polyethylene glycol group. In some other embodiments, the polyethylene glycol-modified phosphatidyl-ethanolamine is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)] (or DSPE-PEG).
[0049] In one specific embodiment, the polyethylene glycol-modified phosphatidylethanolamine (PE) or fatty acid is DSPE-PEG, and the amount of DSPE-PEG is from 0.0001 mol% to 40 mol% of the total lipid content of the liposomes, optionally from 0.01 mol% to 20 mol% as per page 9 / 23 of the specification (CN 121401286 A), and has a PEG portion with an average molecular weight of 2,000 g / mol.
[0050] The terms “liposome-based antiviral agent” or “liposome-based drug” are used interchangeably in this invention. The liposome-based antiviral agent according to this disclosure comprises liposomes encapsulating an antiviral agent, which is prepared by encapsulating the antiviral agent in the aqueous interior of the liposomes via a transmembrane pH gradient-driven remote loading method.
[0051] In some embodiments, liposomes are formed together with a drug component such as hydroxychloroquine or GS-441524 to encapsulate the drug component within the aqueous interior of the liposomes, or empty liposomes with a transmembrane gradient are formed separately for subsequent use in drug loading processes, referred to as active loading methods, also known as remote loading, to form liposomal drugs.
[0052] In some embodiments, the transmembrane pH gradient is generated via the use of a trapping agent, which can be used to remotely load antiviral agents into liposomes, said trapping agent consisting of an ammonium compound and an anion-counterion.
[0053] The term "ammonium compound" includes unsubstituted or substituted ammonium, which is a cation represented as NR4+, wherein each R is independently hydrogen or an organic residue, and said organic residue is independently alkyl, alkylene, heterocyclic alkyl, cycloalkyl, aryl, alkenyl, cycloalkenyl, or their hydroxylated derivatives, optionally containing a sulfur, oxygen, or nitrogen atom in its hydrocarbon chain, forming an ether, ester, thioether, amine, or amide bond. In one specific embodiment,The ammonium compound is ammonium.
[0054] The term "anionic counterion" refers to an anion or an entity covalently linked to an anionic functional group. The anion or anionic functional group carries a negative charge in the physiological environment.
[0055] The anion or anionic functional group may be selected from one or more of the following: sulfate, citrate, sulfonate, phosphate, pyrophosphate, tartrate, succinate, maleate, borate, carboxylate, bicarbonate, glucuronide, chloride, hydroxide, nitrate, cyanate, or bromide.
[0056] In one embodiment, the anion or anionic functional group is selected from one or more of the following: citrate, sulfate, sulfonate, phosphate, pyrophosphate, and carboxylate.
[0057] In yet another embodiment, the entity linked to the anionic functional group may be a natural or synthetic, organic or inorganic compound. Examples of the entities include, but are not limited to, non-polymeric substances selected from alkyl or aryl (e.g., benzene), nucleotides, and sugars. The alkyl group refers to a saturated hydrocarbon group having a specified number of carbon atoms. For example, alkyl groups are selected from the group consisting of: alkyl groups with 1 to 4 carbon atoms (C1-4 alkyl), alkyl groups with 1 to 6 carbon atoms (C1-6 alkyl), alkyl groups with 1 to 8 carbon atoms (C1-8 alkyl), alkyl groups with 1 to 10 carbon atoms (C1-10 alkyl), alkyl groups with 1 to 12 carbon atoms (C1-12 alkyl), alkyl groups with 1 to 14 carbon atoms (C1-14 alkyl), alkyl groups with 1 to 16 carbon atoms (C1-16 alkyl), alkyl groups with 1 to 18 carbon atoms (C1-18 alkyl), and alkyl groups with 1 to 20 carbon atoms (C1-20 alkyl).
[0058] In some embodiments, the anion-counterion is selected from the group consisting of: sulfate, phosphate, citrate, and combinations thereof.
[0059] In some embodiments,The capture agent is selected from the group consisting of ammonium sulfate, ammonium phosphate, ammonium citrate, ammonium sucrose octasulfate, ammonium dextran sulfate, dimethyl ammonium sulfate, dimethyl ammonium phosphate, dimethyl ammonium citrate, diethyl ammonium sulfate, diethyl ammonium phosphate, diethyl ammonium citrate, diethyl ammonium sucrose octasulfate, diethyl ammonium dextran sulfate, trimethyl ammonium sulfate, trimethyl ammonium phosphate, trimethyl ammonium citrate, triethyl ammonium sulfate, triethyl ammonium phosphate, triethyl ammonium citrate, triethyl ammonium sucrose octasulfate, triethyl ammonium dextran sulfate, copper gluconate, copper glucuronide, and combinations thereof.
[0060] In some embodiments, the average particle size of the liposome-like antiviral agent of the present invention is between 50 nm and 1,000 nm. Non-limiting examples of liposome-based antiviral agents have average particle sizes ranging from 50 nm to 20 μm, 50 nm to 10 μm, 50 nm to 1000 nm, 50 nm to 500 nm, 50 nm to 400 nm, 50 nm to 300 nm, 50 nm to 250 nm, 50 nm to 200 nm, 100 nm to 300 nm, or 150 nm to 250 nm.
[0061] In some embodiments, the antiviral agent includes, but is not limited to, antimalarial agents, antiretroviral agents, or combinations thereof. Specifically, the antiviral agent is selected from the group consisting of quinine compounds, nucleoside compounds, and combinations thereof.
[0062] The term "quinine compound" refers to a substance derived from quinine, a lead compound with antimalarial activity extracted from the bark of the cinchona tree. Quinine compounds (e.g., hydroxychloroquine) have been shown to have the potential to inhibit pneumonia progression, improve imaging findings, promote viral negative conversion, and shorten disease course. However, systemic administration of quinine compounds may cause side effects such as blurred vision, nausea, vomiting, abdominal cramps, headache, and diarrhea.
[0063] Quinine compounds according to this disclosure include, but are not limited to, quinine and other 4-aminoquinoline compounds, such as quinine, quinidine, cinconidine, cinconidine, chloroquine (CQ), hydroxychloroquine (HCQ), etc. Exemplary quinine compounds CQ and HCQ have been shown to prevent intracellular organelle acidification and inhibit the release of viral genome lysosomes. In addition,These drugs can interfere with the glycosylation of the angiotensin-converting enzyme 2 (ACE2) receptor on host cells and reduce the binding efficiency between the receptor and the spike protein on the surface of the coronavirus.
[0064] Currently reported potential therapies for RNA virus infection involve nucleosides as inhibitors of non-structural viral proteins, such as RNA-dependent RNA polymerase. Nucleosides are expected to be absorbed by cells and converted into triphosphates in vivo to compete for polymerase nucleotide binding sites, thereby terminating the polymerase chain reaction. This conversion to triphosphates is usually mediated by cellular kinases, which also impose additional structural requirements on potential nucleoside polymerase inhibitors. The monophosphate formed by nucleoside kinases is generally considered to be a rate-determining step of three phosphorylation events. US7,964,580 discloses a pronucleoside containing a phosphoramide moiety that is masked by a neutral lipophilic group to obtain a suitable partition coefficient, thereby optimizing uptake and transport into cells and significantly increasing the intracellular concentration of nucleoside monophosphates compared to administration of the parent nucleoside alone. However, controversial observations suggest that enzyme-mediated hydrolysis of the phosphate ester may produce the nucleoside itself immediately after cycling, rather than producing the target nucleoside monophosphate, and then target the nucleoside to the desired site after production. For example, via intravenous administration, (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxacyclopentane-2-nitrile (also known as GS-441524), a known nucleoside compound, is a more stable remdesivir metabolite than its monophosphate form (Humeniuk R, Mathias A, Cao H, et al. Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. Clin Transl Sci. 2020; 13(5):896-906. doi:10.1111 / cts.12840). Efficiently delivering nucleoside compounds to target cellular sites rich in critical rate-limiting nucleoside kinases could be a universal platform solution that avoids the complex manufacturing processes of different pronucleosides across a wide range of nucleoside compounds.
[0065] In some embodiments, the antiviral composition according to this disclosure further comprises an antibiotic, a supplement, or a combination thereof.
[0066] In some embodiments,The antiviral agent comprises one or more 1'-substituted or 2'-substituted hydrocarbon nucleoside compounds as described in U.S. Patent Nos. US8,008,264 and US9,418,704.
[0067] In some embodiments, the antiviral agent is directed against a nucleoside compound, including but not limited to 1'-substituted hydrocarbon nucleoside compounds and their pharmaceutically acceptable salts.
[0068] In some embodiments, the antiviral agent comprises an inhibitor of RNA-dependent RNA virus polymerase, wherein the inhibitor comprises a nucleoside compound represented by structural formula I: Specification 11 / 23 pages 16 CN 121401286 A (I), each R1, R2, R3, R4 or R5 is independently hydrogen, ORa, N(Ra)2, N3, CN, NO2, S(O)nRa, halogen or methyl, wherein n is 0, 1 or 2; R6 is CN or hydrogen; each Ra is independently hydrogen, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, aryl(C1-C8)alkyl, (C4-C8)carbocycloalkyl, -C(=O)R11, -C(=O)OR11, -C(=O)NR11R12, -C(=O)SR11, -S(O)R11, -S(O)2R 11. —S(O)(OR11), —S(O)2(OR 11), or —SO2NR 11R12; and R7 is hydrogen; each X1 or X2 is independently C-R10 or N; R8 is halogen, NR11R12, N(R11)(OR11), NR11NR11R12, N3, NO, NO2, CHO, CN, —CH(=NR11), —CH=NHNR11, —CH=N(OR11), —CH(OR11)2, —C(=O)NR11R12, —C(=S)NR11R12, —C(=O)OR11, (C1- (C8)alkyl, (C2-C8)alkenyl, (C2-C8)ynyl, aryl(C1-C8)alkyl, (C4-C8)carbocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=O)(C1-C8)alkyl, -S(O)n(C1-C8)alkyl, aryl(C1-C8)alkyl, OR11 or SR11,Each aryl or heteroaryl group is independently and optionally substituted by one or more Z groups; each R9 or R10 is independently hydrogen, halogen, R11, OR11, SR11, NR11R12, N(R11)(OR11), NR11NR11R12, N3, NO, NO2, CHO, CN, —CH(=NR11), —CH=NHNR11, —CH=N(OR11), —CH(OR11)2, —C(=O)NR11R12, —C(=S)NR11R12, —C(=O)OR11; Each R11 or R12 is independently hydrogen, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)ynyl, (C4-C8)carbocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=O)(C1-C8)alkyl, -S(O)n(C1-C8)alkyl, or aryl(C1-C8)alkyl, wherein each aryl or heteroaryl is independently optionally substituted by one or more Z groups; or R11 or R12 together with the nitrogen attached to both of them forms a 3- to 7-membered heterocycle, wherein any carbon atom in the heterocycle may optionally be substituted by -O-, -S-, or -NRa-; each Z group is independently halogen, -O-, =O, -ORb, -SRb, -S-, -NRb2, -N+Rb3, =NRb, - CN, —OCN, —SCN, —N=C=O, —NCS, —NO, —NO2, =N2, —N3, —NHC(=O)Rb, —OC(=O)Rb, —NHC(= O)NRb2, —S(=O)2—, —S(=O)2OH, —S(=O)2R b, —OS(=O)2OR b, —S(=O)2OH, —S(=O)Rb, —OP(= O)(ORb)2, —P(=O)(ORb)2, —P(=O)(O‑)2, —P(O)(ORb)(O‑), —C(=O)Rb, —C(=O)X, —C(S) Rb, -C(O)ORb, -C(O)O-, -C(S)ORb, -C(O)SRb, -C(S)SRb, -C(O)NRb2, -C(S)NRb2, -C(=NRb)NRb2, wherein each Rb is independently hydrogen, alkyl, aryl, aralkyl, or heterocyclic; wherein one or more non-terminal carbon atoms in each of the (C1-C8) alkyl groups are optionally replaced by -O-, -S-, or -NRa-.
[0069] In some embodiments, the antiviral agent is selected from the group consisting of: (Page 12 / 23, CN 121401286 A), (Page 13 / 23, CN 121401286 A), or pharmaceutically acceptable salts thereof.
[0070] In one aspect, the liposome-based antiviral agent comprises: a lipid bilayer,The lipid bilayer comprises: one or more phospholipids, sterols, and optionally polyethylene glycol-modified lipids, particularly polyethylene glycol-modified phosphatidylethanolamine (DSPE-PEG); and an aqueous interior, which is encapsulated by the lipid bilayer and comprises one or more antiviral agents.
[0071] In one embodiment, the one or more phospholipids are neutral phospholipids, and the polyethylene glycol-modified lipids are DSPE-PEG. Based on total phospholipids and sterols, the content of DSPE-PEG is between 0.001 mol% and 5 mol%, optionally between 0.0001 mol% and 40 mol%, optionally less than 6 mol%, optionally between 0.001 mol% and 30 mol%.
[0072] In one embodiment, the liposome-based antiviral composition has a drug-to-lipid ratio (the ratio of the antiviral agent to at least one lipid) of at least 0.01 mol / mol to 0.1 mol / mol and comprises: a lipid bilayer comprising DPPC and cholesterol; and an aqueous interior coated by the lipid bilayer and comprising one or more antiviral agents captured by a trapping agent, wherein the antiviral agent is (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxacyclopentane-2-nitrile (also known as GS-441524), and the trapping agent is ammonium sulfate.
[0073] Inhalable Compositions and Aerosolized Particles The antiviral composition according to the present disclosure is suitable for preparing inhalable aerosolized particle compositions comprising the aforementioned liposome-based antiviral agents. This composition can be administered by inhalation as a nebulized spray or aerosol, and also via intrathecal administration. Inhalation is preferred. Overall, the frequency of administration is lower and the therapeutic index is higher compared to free or parenteral formulations. The liposome-like antiviral agent in the composition is particularly advantageous because the composition is compatible with lung linings or lung surfactants while protecting the drug.
[0074] In one embodiment, the antiviral composition according to this disclosure has the following drug-to-lipid ratio (D / L): at least 0.01 mol / mol, optionally at least 0.1 mol / mol, and preferably between 0.05 mol / mol and 1.0 mol / mol, optionally between 0.01 mol / mol and 0.7 mol / mol, optionally between 0.015 mol / mol and 0.6 mol / mol, and optionally between 0.15 mol / mol and 0.2 mol / mol. The drug-to-lipid ratio refers to the molar ratio of the antiviral agent to at least one lipid. In a particular embodiment,The at least one lipid comprises a neutral phospholipid and a sterol in a molar ratio of 1:1 or 3:2. Optionally, the neutral phospholipid is DPPC, and the sterol is cholesterol.
[0075] In one embodiment, the concentration range of the at least one lipid in the antiviral composition is between 1 mM and 200 mM, between 1 mM and 100 mM, between 5 mM and 100 mM, between 10 mM and 180 mM, between 15 mM and 140 mM, between 20 mM and 160 mM, between 30 mM and 140 mM, and between 40 mM and 120 mM. Alternatively, the concentration range of one or more phospholipids in the antiviral composition may be between 1 mM and 100 mM, between 5 mM and 100 mM, between 5 mM and 90 mM, between 10 mM and 80 mM, between 15 mM and 70 mM, or between 20 mM and 60 mM.
[0076] In one embodiment, the total concentration range of the quinine compound in the antiviral composition is between 0.1 mg / mL and 80 mg / mL, between 0.5 mg / mL and 60 mg / mL, between 1 mg / mL and 30 mg / mL, between 2 mg / mL and 15 mg / mL, between 0.5 mg / mL and 70 mg / mL, between 0.5 mg / mL and 60 mg / mL, between 0.5 mg / mL and 50 mg / mL, between 0.5 mg / mL and 40 mg / mL, between 0.5 mg / mL and 30 mg / mL, between 0.5 mg / mL and 20 mg / mL, between 0.5 mg / mL and 10 mg / mL, between 0.5 mg / mL and 8 mg / mL, between 0.5 mg / mL and 5 mg / mL, between 1.0 mg / mL and 6 mg / mL. The concentration is between mg / mL, between 1.5 mg / mL and 5.0 mg / mL, between 1.5 mg / mL and 4.0 mg / mL, or about 2.0 mg / mL.
[0077] In one embodiment,The concentration range of at least one phospholipid in the antiviral agent composition is between 1 mM and 100 mM, between 5 mM and 100 mM, between 5 mM and 90 mM, between 10 mM and 80 mM, between 15 mM and 70 mM, and between 20 mM and 60 mM; and the drug-to-lipid (D / L) ratio is between 0.01 mol / mol and 1.0 mol / mol, between 0.03 mol / mol and 0.5 mol / mol, between 0.03 mol / mol and 0.15 mol / mol, between 0.03 mol / mol and 0.1 mol / mol, about 0.005 mol / mol, between 0.05 mol / mol and 0.1 mol / mol, between 0.07 mol / mol and 0.09 mol / mol, or about 0.085 mol / L. mol, wherein the antiviral agent is a 1'-substituted hydrocarbon nucleoside compound or a 2'-substituted hydrocarbon nucleoside compound having a free 5'-OH group.
[0078] In some embodiments, the liposome-based antiviral agent composition further comprises a free antiviral agent, and the content of the free antiviral agent in the composition according to the present disclosure is based on the total amount of antiviral agent in the composition being less than 60%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or between 10% and 40%, between 15% and 35%, or between 10% and 30%.
[0079] In some embodiments, the aerosolized particulate composition comprising the composition according to the present disclosure is generated by aerosolizing the composition using an atomizer selected from air-jet nebulizers, ultrasonic nebulizers, vibrating mesh nebulizers, condensation aerosol generators, electro-hydrodynamic nebulizers, or other lung delivery devices known in the art.
[0080] In some embodiments, the mass median aerodynamic diameter of the aerosolized particulate composition is between 0.5 µm and 5 µm, and optionally between 1 µm and 3 µm.
[0081] After the composition according to the present disclosure is aerosolized, the antiviral agent becomes partially free due to liposome leakage from the liposomal form of the antiviral agent.And it is not encapsulated in liposomes. The amount of free antiviral agent generated in the aerosolized composition is less than 60%, 50%, 40%, 30%, 20%, 10%, or 5%; optionally within a controlled percentage range, which ranges from 0.1% to 50%, from 0.5% to 40%, from 0.5% to 30%, from 0.5% to 20%, from 0.5% to 10%, from 0.5% to 5%, from 10% to 50%, from 15% to 45%, from 20% to 45%, and from 25% to 35%.
[0082] In a particular embodiment, the aerosolized particulate composition is delivered to the individual in need via the lungs, exhibiting a release rate of between about 0.5% and 25% per hour based on the administered drug dose, and complete release of the antiviral agent in as little as about 12 to 24 hours.
[0083] The present disclosure is further described with reference to the following specific non-limiting embodiments.
[0084] Examples The following examples illustrate the preparation and properties of certain embodiments of the present disclosure.
[0085] Example 1: Stability of liposomal antiviral agents Specification 15 / 23 pages 20 CN 121401286 A The liposomal antiviral agent according to the present disclosure comprises liposomes with captured antiviral agents, which are prepared by active loading or passive loading of known techniques.
[0086] A. Preparation of liposome-based antiviral agents by active loading I. Preparation of empty liposomes A method for preparing empty liposomes for remote loading is carried out by a thin-film hydration method or a solvent injection method, the method comprising the following steps: 1. Weighing a lipid mixture of phospholipids and cholesterol in a predetermined molar ratio, wherein DSPE-PEG2000 may or may not be present, and then adding them to 10 mL of chloroform in a round-bottom flask; 2. Placing the flask in a rotary evaporator at a suitable temperature according to the lipid composition, stirring the flask to dissolve the lipid mixture, and then placing the flask under vacuum while stirring to evaporate the chloroform to obtain a dry lipid membrane; 3. Adding a capture agent to distilled water and vortexing the solution to dissolve the powder, thereby preparing a capture agent solution (e.g., ammonium sulfate (AS)); 4. Adding the capture agent solution to the dry lipid membrane and stirring at a suitable temperature according to the lipid composition to form a liposome solution; 5. Freezing and thawing the liposome solution with liquid nitrogen and a water bath at a suitable temperature according to the lipid composition to obtain a liposome sample; 6. The obtained liposome sample was extruded through a 0.2 µm polycarbonate membrane and a 0.1 µm polycarbonate membrane at a suitable temperature according to the lipid composition to obtain the designed particle size; 7. The extruded liposome sample was dialyzed.To remove free trapping agent, the sample is then added to a dialysis bag (MWCO: 25 kD), the bag is sealed, and the dialysis bag is stirred in 100 volumes of 9.4% (w / v) sucrose solution, physiological saline, or a suitable buffer solution; the sucrose solution, physiological saline, or a suitable buffer solution is further replaced after 1 hour and 4 hours, and the dialysis bag is stirred overnight; and 8. the dialyzed liposome sample is sterilized by filtration through a 0.45 μm polytetrafluoroethylene (PTFE) membrane to obtain empty liposomes.
[0087] II. Loading antiviral agents into liposomes to obtain liposome-form antiviral agents The following method is an exemplary scheme for encapsulating hydroxychloroquine or chloroquine into liposomes via remote loading, comprising the following steps: 1. Preparing a 40 mg / mL or suitable concentration of hydroxychloroquine or chloroquine solution in a 9.4% (w / v) sucrose solution or a suitable medium, and briefly heating the solution at a suitable temperature to obtain a stock solution containing hydroxychloroquine or chloroquine (hereinafter referred to as stock solution); 2. Mixing empty liposomes (in a typical embodiment, having the following conditions in a typical embodiment: a DPPC:cholesterol molar ratio of 3:2, 300 mM ammonium sulfate (AS) and 30 mM phospholipid concentration), a saline solution and stock solution in a conical tube to obtain a loading solution with a D / L ratio of 100 g / mol or 0.19 mol / mol; 3. Continuously shaking the loading solution at a suitable temperature for 30 minutes or a predetermined time to form a liposome sample loaded with the drug; 4. If necessary, remove free drug or change buffer or adjust drug concentration by dialysis or membrane-based tangential flow filtration (TFF); 5. Use size-exclusion column chromatography and HPLC to determine the drug encapsulation (i.e., loading efficiency) of the final sample to obtain the liposome-like antiviral composition, wherein the drug concentration is between 2 mg / mL and 10 mg / mL, and the ratio of antiviral agent to lipid is between 0.05 mol / mol and 1.5 mol / mol (see Formulations #1 to #3 below).
[0088] B. Preparation of liposome-like antiviral agents by passive loading. Liposomes can be prepared by membrane hydration or solvent injection. The process for preparing liposome-based antiviral agents using solvent injection is specified as a method comprising the following steps: 1. Weighing a lipid mixture of phospholipids and cholesterol in a predetermined molar ratio,1. DSPE-PEG2000 may or may not be present, and then they are added to 10 mL of ethanol in a round-bottom flask to form a solvent phase containing the lipids; 2. Prepare a solution of hydroxychloroquine or chloroquine at a concentration of 40 mg / mL to 60 mg / mL or a suitable concentration in a 0.9% sodium chloride aqueous solution (saline) or a suitable medium to form an aqueous phase; 3. Preheat 40 mL of the aforementioned aqueous phase (40 mg / mL hydroxychloroquine) at 50°C for at least 30 minutes; 4. Add the dissolved lipid mixture (i.e., the solvent phase) to the preheated aqueous phase with stirring using a syringe to form a pro-liposome sample, and then continuously stir the pro-liposome sample at 50°C for 5 minutes; 5. Extrude the pro-liposome sample from a 0.2 µm polycarbonate membrane at a suitable temperature according to the lipid composition to obtain the designed particle size; 6. Dialyze the extruded liposome sample with saline (0.9% NaCl) to remove free drug; and 7. Through 0 The dialyzed liposome sample was sterilized by filtering it through a 0.2µm polycarbonate membrane to obtain a liposome-formed antiviral agent.
[0089] The antiviral agent composition according to this disclosure can be formulated by adding free antiviral agent in a manner targeting an antiviral agent concentration of 1.0 mg / mL to 4 mg / mL, and the ratio of antiviral agent to lipid is at least between 0.05 mol / mol and 0.30 mol / mol (see formulations #4 to #6 below), based on the overall composition.
[0090] C. Storage stability of the liposome-formed antiviral agent The stability of the liposome-formed hydroxychloroquine or chloroquine prepared as described in sections A and B above, stored at 4°C, can be monitored for at least 2 weeks or a predetermined time. Hydroxychloroquine or chloroquine is loaded into empty liposomes by active or passive loading with ammonium sulfate to obtain liposome-formed drug samples for study. After the liposome-formed drug samples are stored at 4°C or a suitable temperature for 2 weeks or a predetermined time, the pharmacodynamics and physicochemical properties of the liposomes can be studied over time.
[0091] Example 2: Preclinical evaluation of inhaled liposomal antiviral agents in animal models. The toxicity of the exemplary liposomal hydroxychloroquine (HCQ) composition (also referred to as TLC19) prepared in Example 1B was studied in the animal datasheet, page 17 / 23, 22 CN 121401286 A. Preliminary conceptual pharmacokinetics (PK) and tissue distribution studies in Sprague-Dawley (SD) rats demonstrated that...The study was performed via a single intravenous (IV) / intrahepatic (IT) administration of HCQ sulfate solution (free HCQ) or an IT administration of the test formulation of TLC19 (study number PK20021). The aim of this study was to investigate the tissue distribution, primarily in the lungs, and the systemic exposure to HCQ.
[0092] A total of 52 rats were randomly assigned to three treatment groups, with each rat receiving a single dose of HCQ via either intratracheal administration or a single IV injection. Blood and organ / tissue samples, including lung samples, were collected at pre-specified time points at 0.25, 1 (blood only), 4, 24, and 72 hours post-administration for HCQ determination by liquid chromatography-tandem mass spectrometry. The study design is summarized in Table 1 below.
[0093] Table 1: Study Design Summary (Study No. PK20021)
[0094] The concentrations of HCQ in blood, lungs, and heart were calculated using Analyst® or MassLynx software, while the pharmacokinetic (PK) parameters were determined using Phoenix® WinNonlin®. The HCQ concentrations in the lungs, blood, and heart versus time after administration of the TLC19 test formulation and free HCQ are shown in Figures 1, 2, and 3, respectively. The mean PK parameters in the lungs, blood, and heart are shown in Table 2 below.
[0095] Table 2: Mean pharmacokinetic parameters in the lungs, blood, and heart of rats after administration of the TLC19 test formulation and free HCQ (Study No. PK20021)
[0096] a: Tmax is the median b: Units for lungs and heart are µg / g; units for blood are µg / mL c: Units for lungs and heart are hr*µg / g; units for blood are hr*µg / mL d: Not applicable For the lung distribution in rats administered free HCQ, the HCQ concentration continued to decrease rapidly during the first 24 hours after administration, especially in the HCQ IT group; in the HCQ IT group, the mean HCQ concentration decreased from 47.8 µg / g to 2.16 µg / g, while in the HCQ IV group, the mean HCQ concentration decreased from 9.4 µg / g to 3.77 µg / g. In contrast, the degree of HCQ deposition in the lungs of the TLC19 (test kit instructions, pages 18 / 23, CN 121401286 A) group was significantly higher than that of the free HCQ group, due to the sustained-release properties of the liposomal drug. During the first 24 hours after administration of half the free HCQ dose, the TLC19 group continued to release HCQ in the lungs for a period of time, during which the average HCQ concentration decreased from 129 µg / g to 57.1 µg / g.
[0097] In the free HCQ IV and free HCQ IT groups, the half-lives of HCQ in the lungs were 15.2 hours and 17.7 hours, respectively.This is consistent with the physicochemical properties of HCQ, which allows it to rapidly and freely cross cell membranes at physiological pH. The half-life of HCQ in the TLC19 (test formulation) group (37.5 hours) was approximately twice that of the free HCQ group. When dose-normalized, the AUC0-72 and Cmax lung exposures in the TLC19 (test formulation) group were 35 and 29 times that of the free HCQ IV group, respectively. These results indicate that TLC19 (test formulation) is a sustained-release formulation of HCQ, successfully prolonging the residence time of HCQ in the lungs compared to free HCQ administered intravenously or intratracheally. In our study, free HCQ, whether administered intravenously or intratracheally, could not maintain HCQ concentrations in the lungs for an extended period.
[0098] Regarding systemic exposure, HCQ is rapidly absorbed and distributed throughout the body after administration. The median Tmax of HCQ in the blood was 0.25 hours after administration in all three groups. In both the free HCQ IV and free HCQ IT groups, the overall systemic exposure, including Cmax and AUC, was similar. For TLC19 (test formulation), the Cmax of HCQ in the blood was significantly lower than that of free HCQ. A small amount of HCQ showed initial peak concentrations within 1 hour after administration of TLC19 (test formulation). The remaining HCQ remained in the lungs, allowing TLC19 (test formulation) to remain for an extended period of 24 to 72 hours after administration and a constant low mean plasma concentration. The lower HCQ plasma concentration levels observed over time indicate that HCQ is gradually released at local sites. As reflected by the longer half-life, the half-life of TLC19 (test formulation) is longer than that of unprepared HCQ solution.
[0099] HCQ has been shown to cause cardiac disease, including prolongation of the corrected QT interval (QTc). To determine the distribution of TLC19 in the heart, we measured HCQ PK curves in cardiac tissue (Figure 3). Compared to HCQ solution, TLC19 has a lower cardiac exposure (Cmax). Similar AUCs were observed in all groups after dose normalization. These results suggest that TLC19 causes less cardiotoxicity than conventional HCQ administration, considering the lower dose required for local (i.e., intratracheal) rather than systemic (i.e., oral or intravenous) administration.
[0100] Two preclinical PK studies for the optimized formulation of TLC19 will be conducted via IT administration in Sprague-Dawley (SD) rats and are detailed below.
[0101] (1) Single-dose pharmacokinetic studies in SD rats: Blood pharmacokinetic and tissue concentration studies can be performed in SD rats following a single IT administration of TLC19. Blood and major organs, including the lungs, can be collected at specified sampling time points; and HCQ concentrations in whole blood and organs can be determined. Thus,The PK curve of TLC19 can be preliminarily determined, and the percentage of TLC19 drug distribution in the lungs can be calculated.
[0102] (2) Multi-dose pharmacokinetic study in SD rats: The study aims to describe and evaluate the drug accumulation of TLC19 after multiple doses of IT administration. Blood and major organs, including the lungs, can be collected at specified sampling time points after the first and last administration. The accumulation rate of TLC19 in blood and lungs is calculated.
[0103] Example 3: Preparation of liposome-based antiviral agent sulfobutyl ether-β-cyclodextrin (SBECD) was purchased from Zibo Qianhui Biotechnology Co., Ltd., China. GS-441524 (containing 1.0 mg / mL GS-441524) prepared by SBECD was prepared by dissolving the antiviral agent GS-441524 in a 150 mg / mL SBECD solution with a pH of approximately 4.4, and was used as test sample (1): GS-441524 solution-IV.
[0104] The research drug (liposome-like GS-441524, also known as ISPM21) was prepared by Taiwan Liposome Co., Ltd. It consists of GS-441524 encapsulated in liposomes with an average particle size of approximately 200 nm. GS-441524 is a pure pale yellow powder provided by Formosa Plastics Pharmaceutical Co., Ltd. The liposomes consist of dipalmitoylphosphatidylcholine (DPPC) (Nippon Fine Chemical Co., Ltd., Japan) and cholesterol (Dishman, Netherlands), both of which are natural components of lung surfactant 23. Empty liposomes were prepared by solvent injection. Simply put, an appropriate amount of the lipid mixture (dipalmitoyl-sn-glycerol-3-phosphatidylcholine (DPPC) and cholesterol) was dissolved in ethanol (JT Baker, USA) and then injected into an ammonium sulfate solution while stirring at 50°C. Using an extruder, the liposomes were extruded from a 0.2 µm polycarbonate membrane at 50°C, thereby adjusting the size of the liposomes to about 200 nm. The unencapsulated ammonium sulfate and ethanol were removed by percolation to obtain the final empty liposomes.
[0105] GS-441524 was encapsulated in the liposomes using an active loading method. Pre-formed empty liposomes were mixed with the GS-441524 drug solution and then incubated at 50°C to obtain the final ISPM21 sample (liposomal drug suspension) with a pH between 6 and 7.And as test sample (2): ISPM21-IT.
[0106] A. Preparation of liposome nucleoside compounds I. Preparation of empty liposomes Liposomes are prepared by thin-film hydration or solvent injection.
[0107] The process for preparing empty liposomes by solvent injection is specified as a method comprising the following steps: 1. Weighing a lipid mixture of phospholipids and cholesterol in a predetermined molar ratio, wherein DSPE-PEG200 is present or absent, and then dissolving them in ethanol at an elevated temperature; 2. Adding a capture agent to distilled water and then mixing the solution to dissolve salts, thereby preparing a capture agent solution (e.g., ammonium sulfate (AS)); 3. Adding the lipid mixture to the capture agent solution at a suitable temperature according to the lipid composition to form a liposome solution; 4. Extruding the resulting liposome solution from a polycarbonate membrane at a suitable temperature according to the lipid composition to obtain the desired particle size; 5. Percolating the extruded liposomes relative to a sucrose solution or saline or a suitable buffer solution to remove free capture agent and ethanol.
[0108] II. Loading antiviral agents into liposomes The following method is an exemplary scheme for encapsulating nucleoside compounds into liposomes via remote loading, comprising the following steps: 1. Preparing a solution of nucleoside compound at a concentration of 15.4 mg / mL or a suitable concentration in a suitable medium to obtain a stock solution containing the nucleoside compound (hereinafter referred to as stock solution); 2. Mixing empty liposomes prepared by the process of Example 1, Section A, Section I (in a typical specific embodiment, having the following conditions: a molar ratio of DPPC to cholesterol of 3:2, 300 mM ammonium sulfate (AS) as a capture agent, and a phospholipid concentration of 20-50 mM) and the stock solution in an Erlenmeyer flask to obtain a loading solution with a D / L ratio of 25 g / mol or a predetermined D / L ratio; 3. Continuously shaking the loading solution at a suitable temperature for 60 minutes or a predetermined time to form drug-loaded liposomes; 4. Adding sodium hydroxide solution or buffer solution to the drug-loaded liposomes to adjust the pH to between 6 and 7; and 5. Size-exclusion column chromatography and UV-Vis absorbance measurement or HPLC analysis were used to determine the drug encapsulation (i.e., loading efficiency) of the final sample.
[0109] Table A: Drug loading amount at different drug lipid ratios. (Instructions for Use, Page 20 / 23, 25 CN 121401286 A)
[0110] *Encapsulation efficiency (encapsulation efficiency, ...)EE) is calculated by the following formula: liposomal drug (LF) divided by all types of drugs (TF): EE (%) = LF / TF*100%.
[0111] B. Storage stability of liposomal antiviral agents The stability of liposomal nucleoside compounds stored at 4°C can be monitored for at least 2 months or a predetermined time. The nucleoside compounds were loaded into empty liposomes using 300mM ammonium sulfate or 75mM sucrose octaethylammonium sulfate as capture agents to obtain liposomal drug samples (Table A). After the liposomal drug samples were stored at 4°C or a suitable temperature for 2 months or a predetermined time, the pharmacodynamics and physicochemical properties of the liposomes were studied over time.
[0112] Example 4: Release characteristics of liposomal antiviral agents In vitro drug release in simulated lung fluid The release characteristics experiment of the liposomal antiviral agents prepared in Example 1 was performed to demonstrate their sustained-release properties. The in vitro release (IVR) assay protocol is as follows: 1. Mix 0.5 mL of each liposome-based antiviral agent sample with 4.5 mL of simulated lung fluid (preheated to 37°C), thereby diluting the test sample 10-fold. Then, place the diluted sample into a 15 mL centrifuge tube; 2. Place the centrifuge tube containing the diluted sample onto the sample well of an Inteli-mixer vortex mixer, rotate at 20 rpm, and incubate at 37°C; 3. At predetermined time points, take 1 mL of the diluted sample to analyze the encapsulation efficiency.
[0113] The analytical method for determining the encapsulation efficiency of nucleoside compounds is as follows: a. Fill and wash a 2 mL G50 column with condition solution; b. Add 0.1 mL of sample to the column, then add 0.45 mL of eluent and wait for the solution to elute from the column; c. Add 0.8 mL of eluent to the column and collect the liposome eluent; d. Dissolve the pre-column and post-column samples (liposome form and all forms) with a suitable solvent; and e. Measure the absorbance of the sample at a specified wavelength using UV-Vis or HPLC to determine the drug concentration of each sample.
[0114] The encapsulation efficiency (EE) of the antiviral agent in liposomes is calculated by the following formula: drug in liposome form (LF) divided by drug in all forms (TF): EE (%) = LF / TF*100%.
[0115] A release curve can be plotted to describe the relationship between the release rate (%) and time. The release rate is calculated by the following formula: initial liposome form minus the liposome form at each time point.Divide by the initial liposome form: (LFt0-TFt) / LFt0*100%.
[0116] In order to achieve improved efficacy and treatment at a low dosing frequency, it is desirable to have a prolonged release characteristic of the drug component. Therefore, we selected liposomal antiviral agents with slow or suitable release characteristics from all formulations and used them to conduct the following toxicity studies. Instructions for Use, Pages 21 / 23, 26, CN 121401286 A
[0117] Example 5: Pharmacokinetic Study of Inhaled Liposome Antiviral Agent in Animal Model A total of 48 female SD rats were divided into two treatment groups: (1) GS-441524 solution-IV: 24 rats were given a single intravenous injection of GS-441524 at a dose of 0.20 mg / rat; (2) ISPM21-IT: 24 rats were given a single administration of 0.20 mg ISPM21 (a liposomal suspension containing 1.0 mg / mL GS-441524) via IT, which is a clinically simulated inhalation route of administration. Blood samples were collected at 0.25, 1, 4, 24, and 72 hours after administration, while lung samples were collected at 0.25, 4, 24, and 72 hours after administration. All surgeries involving animals were performed at the TLC animal facility and in accordance with the ethical guidelines of the TLC’s Laboratory Animal Care and Use Committee (IACUC) (#TLC20IACUC037).
[0118] Blood and lung sample collection and processing: Blood was collected from the jugular vein at the prescribed sampling time points and placed in collection tubes containing K2EDTA as an anticoagulant. Each collection tube was gently inverted to ensure complete mixing of the sample with the anticoagulant. The actual sampling time was recorded. The collected blood samples were centrifuged at 1500xg for 10 minutes at 2–8°C to obtain plasma. The supernatant plasma was immediately transferred to labeled microtubes. If not processed immediately, the plasma was transferred to a freezer at -80°C. Plasma collection must be completed within two hours of blood collection.
[0119] Animals were euthanized within the prescribed lung sample collection time. Each rat was perfused with approximately 100 mL of 2 mM K2EDTA / saline using a KD Scientific® injection pump for at least 8 minutes. The lungs were removed after perfusion and frozen with liquid nitrogen. After freezing, the lungs were weighed and placed on wet ice until transferred to a freezer at -80°C. All lung samples were stored at -80°C until homogenized.
[0120] Bioanalysis and pharmacokinetic (PK) calculations: An internal standard (6,7-dimethyl-2,3-di-2-pyridylquinoxaline) was added to the blood samples before thorough mixing with methanol to precipitate proteins. After centrifugation,The supernatant was injected into a Waters Class I UPLC coupled to a Waters Xevo™ TQ-S tandem mass spectrometer (LC-MS / MS) for analysis. For lung samples, tissue / organ homogenates were homogenized with 50% methanol and 0.1% formic acid. An internal standard (IS) was added to the tissue / organ homogenate before thorough mixing with methanol to precipitate proteins. After centrifugation, the resulting sample supernatant was injected into LC-MS / MS for analysis. The concentration of GS-441524 was calculated using MassLynx software. The linear ranges for lung and plasma analyses were 10–10000 ng / mL and 0.5–500 ng / mL, respectively. The pharmacokinetic parameters of GS-441524 were calculated using a non-compartmental method with Phoenix® WinNonlin® (8.0 or later) and sparse sampling computation.
[0121] Results of pharmacokinetics of GS-441524 in the lungs: Following a single administration of ISPM21 as an IT, ISPM21-IT showed a longer half-life (22.8 h) and higher GS-441524 concentrations in the lungs compared to GS-441524 solution-IV (Table 3) (Figure 4A). Since concentrations were only measurable at the first time point (0.25 h), the half-life and AUC of GS-441524 solution-IV in the lungs could not be calculated. Notably, the Cmax of a single 0.2 mg dose of ISPM21-IT was 74.9 µg / g, and the AUC0-72 was 369 h* µg / g, indicating a significantly increased lung exposure compared to GS-441524 solution-IV, with the Cmax of ISPM21-IT being 207 times that of GS-441524 solution-IV (Table 4).
[0122] Table 3: Pharmacokinetic (PK) parameters of GS-441524 in rat lungs and plasma after single administration of GS-441524 solution-IV and ISPM21-IT. (Instructions for Use, Pages 22 / 23, 27 CN 121401286 A)
[0123] Table 4: Ratio of ISPM21-IT to GS-441524 solution-IV, representing the dose-normalized maximum concentration and area under the concentration-time curve.
[0124] Pharmacokinetics of GS-441524 in plasma: After a single administration, compared to GS-441524 solution-IV,ISPM21-IT exhibited similar PK properties in plasma (Figure 4B) and AUC (Tables 3 and 4). The plasma half-life of ISPM21-IT (9.98 hours) was slightly longer than that of GS-441524 solution-IV (7.43 hours). Notably, ISPM21-IT showed a lower systemic exposure in plasma (37% of Cmax) compared to GS-441524 solution-IV (Table 4).
[0125] In this rat PK study, we investigated the targeted delivery of inhalable ISPM21 to the lungs and showed sustained release of GS-441524 to the lungs and significantly higher exposure. Following a single IT administration of ISPM21, the mean concentration of GS-441524 in lung tissue was 1.07 µg / g (3.67 µM, assuming a lung tissue sample density of 1 g / mL) 72 hours after administration, indicating that ISPM21 can maintain a relatively high concentration of GS-441524.This is 19 times higher than the in vitro antiviral EC50 (0.18 µM) against human airway epithelial (HAE) cells infected with SARS-CoV. Instruction manual, 23 / 23 pages, 28 CN 121401286 A, Figure 1; Instruction manual, Figure 1 / 4 pages, 29 CN 121401286 A, Figure 2; Instruction manual, Figure 2 / 4 pages, 30 CN 121401286 A, Figure 3; Instruction manual, Figure 3 / 4 pages, 31 CN 121401286 A, Figure 4A, Figure 4B; Instruction manual, Figure 4 / 4 pages, 32 CN 121401286 A, Abstract: The present application relates to a composition of antiviral agent for use in prophylaxis or treatment against pathogenic infection and its use. The liposomal antiviral agent of the composition includes a liposome and an antiviral agent entrapped in the liposome. The antiviral agent has been stably encapsulated in the liposome, and the resulting liposomal antiviral agent is proven to be stably aerosolized or nebulized for administration via the inhalation route to treat a subject in need thereof with Reduced side effect.
Claims
1. An antiviral composition for inhalation administration, comprising a liposomal antiviral agent, wherein the liposomal antiviral agent comprises: Liposomes, wherein the liposomes comprise at least one lipid. Capture agent, and Antiviral agents; The antiviral agent is encapsulated in the liposome by the trapping agent. The trapping agent is composed of an ammonium compound and anions and counterions. The molar ratio of the antiviral agent to the lipid is from 0.01 mol / mol to 2.0 mol / mol, and The antiviral agent described herein is a nucleoside compound of structural formula (I): (I), Each R 1 R 2 R 3 R 4 Or R 5 Independently for hydrogen, OR a 、N(R a 2, N3, CN, NO2, S(O) n R a , halogen or methyl, where n is 0, 1 or 2; R 6 It can be CN or hydrogen; Each R a Independently, it can be H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)ynyl, aryl(C1-C8)alkyl, (C4-C8)carbocycloalkyl, or —C(=O)R 11 —C(=O)OR 11 —C(=O)NR 11 R 12 —C(=O)SR 11 —S(O)R 11 —S(O)2R 11 —S(O)(OR) 11 —S(O)2(OR) 11 ), or —SO2NR 11 R 12 ;as well as R 7 It is hydrogen; Each X 1 or X 2 Independent for CR 10 Or N; R 8 Halogen, NR 11 R 12 、N(R 11 (OR) 11 ) , NR 11 NR 11 R 12 , N3, NO, NO2, CHO, CN, —CH(=NR 11 ), —CH=NHNR 11 —CH=N(OR 11 —CH(OR) 11 )2、—C(=O)NR 11 R 12 —C(=S)NR 11 R 12 —C(=O)OR 11 (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)ynyl, aryl(C1-C8)alkyl, (C4-C8)carbocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=O)(C1-C8)alkyl, -S(O) n (C1-C8)alkyl, aryl(C1-C8)alkyl, OR 11 or SR 11 Each aryl or heteroaryl group is independently and optionally substituted by one or more Z groups; Each R 9 Or R 10 Independently hydrogen, halogen, R 11 OR 11 SR 11 NR 11 R 12 、N(R 11 (OR) 11 ), NR 11 NR 11 R 12 , N3, NO, NO2, CHO, CN, —CH(=NR 11 ), —CH=NHNR 11 -CH=N(OR) 11 —CH(OR) 11 )2、—C(=O)NR 11 R 12 —C(=S)NR 11 R 12 —C(=O)OR 11 ; Each R 11 Or R 12 Independently, it is hydrogen, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)ynyl, (C4-C8)carbocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -C(=O)(C1-C8)alkyl, -S(O). n (C1-C8)alkyl or aryl(C1-C8)alkyl, wherein each aryl or heteroaryl group is independently and optionally substituted by one or more Z groups; or R 11 Or R 12 Together with the nitrogen atom attached to both of them, they form a 3- to 7-membered heterocycle, wherein any carbon atom in the heterocycle may optionally be replaced by —O—, —S— or —NR. a -replace; Each Z group is independently a halogen, -O - =O, —OR b —SR b —S- —NR b 2、—N + R b 3. =NR b , —CN, —OCN, —SCN, —N=C=O, —NCS, —NO, —NO2, =N2, —N3, —NHC(=O)R b —OC(=O)R b —NHC(=O)NR b 2. —S(=O)2—, —S(=O)2OH, —S(=O)2R b —OS(=O)2OR b —S(=O)2OH, —S(=O)R b —OP(=O)(OR) b )2、—P(=O)(OR b )2, —P(=O)(O-)2, —P(O)(OR b (O-), —C(=O)R b —C(=O)X, —C(S)R b —C(O)OR b —C(O)O-, —C(S)OR b —C(O)SR b —C(S)SR b —C(O)NR b 2、—C(S)NR b 2、—C(=NR b )NR b 2, where each R b Independently hydrogen, alkyl, aryl, aralkyl, or heterocyclic, wherein one or more non-terminal carbon atoms in each of the (C1-C8) alkyl groups are optionally surrounded by —O—, —S—, or —NR. a -replace.
2. The antiviral composition according to claim 1, wherein the antiviral agent is selected from: 、 、 、 、 、 、 Or its pharmaceutically acceptable salt.
3. The antiviral composition according to claim 1, wherein the at least one lipid comprises one or more phospholipids and sterols, and the molar ratio of total phospholipids to the sterols is 1:1 to 2:
1.
4. The antiviral composition according to claim 3, wherein the sterol is cholesterol.
5. The antiviral composition according to claim 1, wherein the at least one lipid is selected from the group consisting of: hydrogenated soybean phosphatidylcholine (HSPC), 1,2-distearyl-sn-glycerol-3-phosphorylcholine (DSPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphorylcholine (DPPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphorylethanolamine (DPPE), and combinations thereof.
6. The antiviral composition according to claim 1, wherein the average particle size of the liposome-based antiviral agent ranges from 50 nm to 1000 nm.
7. The antiviral composition according to claim 1, wherein the anion and counterion are selected from: sucrose octasulfate, dextran sulfate, sulfate, citrate, glucuronide, sulfonate, phosphate, pyrophosphate, tartrate, succinate, maleic acid, borate, carboxylate, bicarbonate, glucuronide, chloride, hydroxide, nitrate, cyanate, bromide, and combinations thereof.
8. The antiviral composition of claim 3, wherein the liposomes further comprise polyethylene glycol (PEG) modified lipids, wherein the amount of the PEG modified lipids is from 0.0001 mol% to 10 mol% based on total lipids.
9. The antiviral composition of claim 8, wherein the polyethylene glycol-modified lipid has a polyethylene glycol portion having an average molecular weight ranging from about 1,000 g / mol to about 5,000 g / mol.
10. The antiviral pharmaceutical composition according to claim 8, wherein the polyethylene glycol-modified lipid is 1,2-distearate-sn-glycerol-3-phosphorylethanolamine-N-[methoxy(polyethylene glycol)] (DSPE-PEG).
11. The antiviral pharmaceutical composition of claim 10, wherein the amount of DSPE-PEG is from about 0.001 mol% to about 5 mol% based on total phospholipids and sterols.
12. The antiviral composition according to claim 1, further comprising an antibiotic.
13. The antiviral composition according to claim 12, wherein the antibiotic is selected from azithromycin and azithromycin.
14. The antiviral composition of claim 1, wherein the concentration of the lipid is from 1 mM to 100 mM.
15. The antiviral composition according to claim 1, further comprising a free antiviral agent.
16. The antiviral composition according to claim 1, wherein the molar ratio of the antiviral agent to the lipid is from 0.05 mol / mol to 2.0 mol / mol.
17. The antiviral composition of claim 1, wherein the amount of said antiviral agent is from about 0.1 mg / mL to about 80 mg / mL.
18. The antiviral composition according to claim 1, wherein the antiviral composition is an atomizing spray.
19. An aerosolized particulate composition comprising an antiviral composition according to any one of claims 1 to 18, the aerosolized particulate composition being intended for administration via inhalation to prevent or treat infectious or respiratory diseases.
20. The aerosolized particulate composition of claim 19, wherein the median mass aerodynamic diameter of the plurality of particles is about 0.5 µm to about 5 µm.
21. Use of the antiviral composition according to any one of claims 1 to 18 in the preparation of a medicament for treating or preventing infectious or respiratory diseases.
22. The use according to claim 21, wherein the respiratory disease is selected from: acute respiratory infection with severe pneumonia (SARI), acute respiratory distress syndrome (ARDS), sepsis, and septic shock.
23. The use according to claim 21, wherein the infectious disease is caused by an influenza virus, a retrovirus, a coronavirus, or SARS-CoV-2.
24. Use of the antiviral composition according to any one of claims 1 to 18 in the preparation of a medicament for reducing complications associated with the treatment of respiratory or infectious diseases in human individuals.
25. The use according to claim 24, wherein the complications include cardiotoxicity or hepatotoxicity.
26. The use according to claim 24, wherein the complication includes correction of QT interval (QTc) prolongation.
